Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situ
Hematogenous tumor cell dissemination is a crucial step in systemic disease progression and predicts reduced clinical outcome in breast cancer patients. Only invasive cancers are assumed to shed tumor cells into the bloodstream and infiltrate lymph nodes. However, recent studies revealed that dissem...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
4 March 2014
|
| In: |
Breast cancer research and treatment
Year: 2014, Volume: 144, Issue: 3, Pages: 531-538 |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-014-2898-6 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1007/s10549-014-2898-6 Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007%2Fs10549-014-2898-6 |
| Author Notes: | Malgorzata Banys, Markus Hahn, Ines Gruber, Natalia Krawczyk, Markus Wallwiener, Andreas Hartkopf, Florin-Andrei Taran, Carmen Röhm, Ralf Kurth, Sven Becker, Erich-Franz Solomayer, Diethelm Wallwiener, Annette Staebler, Tanja Fehm |
| Summary: | Hematogenous tumor cell dissemination is a crucial step in systemic disease progression and predicts reduced clinical outcome in breast cancer patients. Only invasive cancers are assumed to shed tumor cells into the bloodstream and infiltrate lymph nodes. However, recent studies revealed that disseminated tumor cells (DTCs) may be detected in bone marrow (BM) of patients with preinvasive lesions, i.e., ductal carcinoma in situ (DCIS). The purpose of this analysis was to examine the incidence and clinical value of DTC detection in a large series of patients with pure DCIS. 404 patients treated for DCIS at the University Hospital Tuebingen, Germany were included into this analysis. |
|---|---|
| Item Description: | Gesehen am 21.08.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-014-2898-6 |